References
- Amraoui, A., Burgos, V., Baron, P., & Alexandre, J. Y. (1999). Acute delirium psychosis induced by naltrexone chlorhydrate. Presse medicale (Paris, France: 1983), 28(25), 1361.
- Bolton, M., Hodkinson, A., Boda, S., Mould, A., Panagioti, M., Rhodes, S., Riste, L., & van Marwijk, H. (2019). Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: A systematic review and meta-analysis. BMC Medicine, 17(1), 1–13. https://doi.org/10.1186/s12916-018-1242-0
- Christou, G. A., & Kiortsis, D. N. (2015). The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: An update. Hormones, 14(3), 370–375. https://doi.org/10.14310/horm.2002.1600
- Eichaar, G. M., Maisch, N. M., Augusto, L. M. G., & Wehring, H. J. (2006). Pediatrics efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Annals of Pharmacotherapy, 40(6), 1086–1095. https://doi.org/10.1345/aph.1G499
- Gitlin, M. J., Gerner, R. H., & Rosenblatt, M. (1981). Assessment of naltrexone in the treatment of schizophrenia. Psychopharmacology, 74(1), 51–53. https://doi.org/10.1007/BF00431756
- Lee, D. B., Woo, Y. S., & Bahk, W. M. (2019). Naltrexone-associated visual hallucinations: A case report. Clinical Psychopharmacology and Neuroscience, 17(2), 329. https://doi.org/10.9758/cpn.2019.17.2.329
- Marchesi, G. F., Santone, G., Cotani, P., Giordano, A., & Chelli, F. (1992). Naltrexone in chronic negative schizophrenia. Clinical Neuropharmacology, 15(1), 56A–57A. https://doi.org/10.1097/00002826-199201001-00031
- Margolis, E. B., Hjelmstad, G. O., Bonci, A., & Fields, H. L. (2005). Both kappa and mu opioid agonists inhibit glutamatergic input to ventral tegmental area neurons. Journal of Neurophysiology, 93(6), 3086–3093. https://doi.org/10.1152/jn.00855.2004
- Sullivan, J. R., & Watson, A. (1997). Naltrexone: A case report of pruritus from an antipruritic. Australasian Journal of Dermatology, 38(4), 196–198. https://doi.org/10.1111/j.1440-0960.1997.tb01696.x
- Tao, R., & Auerbach, S. B. (2005). μ-Opioids disinhibit and κ-opioids inhibit serotonin efflux in the dorsal raphe nucleus. Brain Research, 1049(1), 70–79. https://doi.org/10.1016/j.brainres.2005.04.076